Innoviva Inc

Innoviva, Inc. is a prominent healthcare-focused asset management company that is driving growth and innovation in the pharmaceutical industry through its strategic initiatives and commitment to developing cutting-edge bio-pharmaceutical solutions.

Innoviva, Inc. is a healthcare-focused asset management company navigating the pharmaceutical industry with a focus on bio-pharmaceutical development and commercialization.

Innoviva Inc.’s subsidiary has achieved a milestone in the fight against gonorrhea with the FDA’s acceptance of a new antibiotic, zoliflodacin, for Priority Review.